Anstee QM, Lawitz EJ, Alkhouri N, et al. - Given that accurate noninvasive tests (NITs) are required to substitute liver biopsy for identifying advanced fibrosis caused by NASH, researchers examined screening data from two phase 3 trials of selonsertib in order to evaluate the ability of NITs to distinguish advanced fibrosis. The connections between fibrosis stage and NITs, including the NAFLD fibrosis score, Fibrosis-4 index, Enhanced Liver Fibrosis test, and liver stiffness by vibration-controlled transient elastography (LS by VCTE), were investigated. Utilizing areas under the receiver operating characteristic curve with 5-fold cross-validation repeated 100 times, they assessed the performance of these tests to distinguish advanced fibrosis, either alone or in combinations. Findings suggested that NITs alone or in combination may reduce the need for a liver biopsy to discriminate against advanced fibrosis caused by NASH among patients considered for enrollment in clinical trials. In a real-world population, the predictive value of these tests for general screening will need confirmation.